Quanterix said on Thursday that it has priced a public offering of 3,571,428 shares of its common stock at $70.00 per share. The Billerica, Massachusetts-based firm expects gross proceeds of around $250 million from the offering, which it announced on Wednesday.
The company has granted the underwriters a 30-day option to purchase up to an additional 535,714 shares of common stock at the public offering price less underwriting discounts, commissions, and offering expenses.
Goldman Sachs, SVB Leerink, and Cowen are the joint bookrunning managers for the offering, and Canaccord Genuity is the lead manager.
The offering is expected to close on Feb. 8.
Last month, Quanterix received Emergency Use Authorization from the US Food and Drug Administration for its Simoa SARS-CoV-2 N Protein Antigen Test.